Pharmafile Logo

Blog: The Future of Food Allergy? The Emergence of Targeted Allergy Treatments

May 2, 2019 | Nutritions, Pharma, allergy, healthcare 

Research Analyst Rachel Arthurs explores how public exposure to the complications of food allergy has affected attitudes toward treatment.

In recent years, there has been a noticeable shift in the increased public awareness of allergy-related complications both within the United Kingdom and globally. In 2010, Allergy UK estimated that at least 44% of British adults were currently suffering from at least one allergy, a statistic that only continues to rise steadily each year. In the United States, Statista reported that approximately 20% of American adults in 2017 were suffering from an allergy or food intolerance. The growing interest in allergy shown by the British public was further amplified by the widespread outrage in 2017, following an incident in which a teenage customer of a popular British sandwich chain experienced anaphylaxis as a direct result of inadequate allergen labelling. This is not an isolated incident, but a constant fear and source of anxiety for allergy sufferers all over the world.

Read the full blog here: https://bit.ly/2VCPwf0

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

The Next Billion Patients

Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.

Huge Untapped Growth Potential of ASEAN

Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.

The power of observation in gathering patient insights

Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding.

Market Insights Can Deliver a Better Patient Experience

Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding

Excellence in oncology: Developing an effective biomarker strategy

Oncology is arguably the most exciting area of medicine in which to be working today. Biomarkers and companion diagnostics offer incredibly valuable predictive power, which is of benefit to payers,...

Warehousing of HCV patients reaches new high

A new study conducted by Research Partnership reveals that 90% of physicians treating HCV patients in the US have reported they are now “warehousing” patients (holding off treatment) in expectation...

Brand leaders in RA will lose market share, predict rheumatologists

Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.

Removing the Roadblocks to Effective Patient Treatment

How can pharma benefit from improved patient understanding? Welcome to a new column in which Mary Assimakopoulos, Founding Director of pharma market research specialist the Research Partnership reveals findings from...

Driving Earlier Diagnosis: A Case Study in Psoriatic Arthritis

Following a survey of 1000 Psoriatic Arthritis patients, Mary Assimakopoulos shares some of the root causes behind a late diagnosis of this debilitating illness, and the patients’ own feelings towards...

The Difficulties of Living with Depression Don’t End with the Illness Itself

This month Mary Assimakopoulos examines some of the insights gathered while surveying 2,000 patients suffering with this often misunderstood mental illness.